Introduction
Endometrial cancer (EC) is the most common gynaecological cancer amongst women in the UK. The incidence has increased by about 50% since the 1990s (National Statistics, UK) because of rising obesity rates. Approximately 99,000 new cases were reported in Europe in 2012 (National Statistics, UK) and the most recent UK data in 2011, revealed a total of 8475 new cases reported that year (National Statistics, UK). It is postulated that every day, 23 women are newly diagnosed with EC in the UK. EC not only causes physical and psychological morbidity but, it is also a huge economic burden. The cost of EC treatment in the USA for example, is over USD14, 000 per case (Fanning, 1999 ).
Screening, prevention strategies and survival rates also remain poor in comparison to other endocrine cancers where prognosis has improved. Traditionally, chronic exposure to unopposed estrogen, hyperinsulinaemia and obesity are thought to be key predisposing factors to developing EC (Arem et al, 2013; Burzawa et al, 2011) . These risk factors are also present in women with polycystic ovary syndrome (PCOS) which affects approximately 10% ) of women in the general population and who are three times more likely to develop EC (Barry et al, 2014) . A study reported that the prevalence of EC in PCOS women was 20-37% (Navaratnarajah et al, 2008 ). The precise molecular mechanisms which increase EC risk in women with PCOS are however, unclear (Hardiman et al, 2003; .
It has been hypothesized that insulin resistance plays the key role in the development of EC in women with PCOS and that measures which improve insulin sensitivity such as metformin and weight loss might play a key role in preventing the development of EC in women with PCOS (Shafiee et al, 2014) . The specific expression of genes related to the insulin signalling pathway including the IGF system in the endometrium of women with PCOS has however never been measured and compared to that in women with EC without PCOS and control women without EC or PCOS.
Evidence in support for the hypothesis that insulin resistance plays the key role in the development of EC in women with PCOS is underpinned by the following studies. Diabetes mellitus is linked with EC and even in women receiving exogenous oestrogens, women with diabetes are at higher risk (Harding et al, 2014) ; higher insulin levels have been found in postmenopausal women (who have low oestrogen levels) with EC (Ayabe et al, 1997, Nagamami and Stuart, 1998); insulin and insulin like growth factor (IGF) receptors have been identified in both normal and malignant (Ayabe et al, 1997) endometrium; Insulin, IGF 1 and IGF 2 have been shown to have a mitogenic effect on endometrial cells in-vitro with type I IGF receptor mRNA over-expressed in EC (Nagamani 1991 ) and the number of type I IGF receptors present has been shown to positively correlate with the histological grade of EC (Nagamani et al 1991 , Talavera et al 1990 . Genomic (Pillay et al, 2005) and proteomic (Galazis et al, 2013 ) approaches have also identified potential new genes and proteins which might explain link between PCOS and EC and could up-regulate genes with the insulin signaling pathway in PCOS. A review by Shafiee et al, evaluating possible mechanisms underpinning the molecular links between M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 PCOS and EC suggested that the mitogenic effect of high levels of insulin may be mediated through activation of the phosphatidylinositide 3-kinases (PI3K) /Protein kinase B (Akt) and Ras/microtubule-associated protein kinase (MAPK) signaling pathways and that triggering these pathways results in the exaggeration of IGF1 and IGF binding protein (IGFBP) expression which leads to promotion of cell growth. Measuring the specific expression of genes related to the insulin signaling pathway in the endometrium of women with PCOS compared to that in women with EC and control women without EC or PCOS is however a necessary first step to investigating how these pathways, genes and proteins interact with the insulin signaling pathways in the endometrium of women with PCOS and how this might lead to EC.
Phosphatase and tensin homolog (PTEN) is a tumour suppressor gene located at chromosome 10q23 that suppress cell proliferation and differentiation and is involved in the insulin signaling pathway. The protein encoded by this gene has similar protein tyrosine phosphatase property that negatively regulates PI3K/ Akt signaling pathway involved in carcinogenesis (Scully et al, 2014) Dysfunction of this gene has been implicated in the development of various cancers in the human including breast, ovarian and EC. In type 1 EC, mutation of PTEN occurs in 25-83% of tumours (Melissa et al, 2010) . Interestingly, it has been shown that in EC, PTEN inactivation almost always occurs at an early cancer stage whereas, in other neoplasms PTEN is implicated at the later stages or during metastasis (Melissa et al, 2010) . PTEN gene expression has however never previously been measured in endometrial tissue from women with PCOS in human as far as we know, although an animal study on a rat model of PCOS (using human chorionic gonadotrophine and norethindrone injection) showed that the expression of PTEN gene and protein was significantly increased in ovarian tissue (Ouyang et al, 2013) .
The aim of this study was to test the hypothesis that insulin signaling plays a key role in the development of EC in women with PCOS by measuring and comparing the expression of three key genes involved in the insulin signaling pathway (IGF1, PTEN and IGFBP1) in endometrial tissue obtained from three groups of women; PCOS without EC, women with EC without PCOS and non-PCOS women without EC (controls). This was considered clinically important, because establishing a clear role for the insulin signaling pathway in the mechanisms leading to EC in PCOS would justify clinical trials investigating the use of Metformin and other insulin sensitizers for the prevention of EC in PCOS as well as act as the molecular basis to inform future personalized medicine approaches to match patient's therapies as we currently do not know which subgroups of women with PCOS will go on to develop EC. performed by the designated gynaecological oncologist. On retrieval of the uterus, the hysterectomy (uterus) specimen was taken from the operating theatre to the histology laboratory where a designated a pathologist (whom was alerted before the procedure) immediately performed a cutsection and gross inspection, before some tissue samples were provided to the researcher for snap freezing in liquid nitrogen at minus 80 degrees centigrade. Experimental samples were then transported to the laboratory for storage in freezer at minus 80 degrees centigrade for future analysis.
Methods

Study Design and ethics (institutional review board) approval.
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Women in the control group were identified and recruited from the gynaecology clinics. Following verbal and written informed consent, a clinical assessment was performed and venepunctures performed for endocrine and metabolic assays. Samples were transported and stored for future analysis as was done in women with PCOS. Endometrial samples were taken during the planned operative pelvic procedure by the researcher using a Pipelle® endometrial sample, uterine curette or by direct excision from the uterine specimen as indicated by the type of gynaecological procedure being performed. Samples were snap frozen in liquid nitrogen at minus 80 degrees centigrade and then transported to the laboratory for storage in freezer at minus 80 degrees centigrade for future analysis.
Endocrine and Metabolic Assays
The assays for the endocrine and metabolic study were performed in the clinical chemical laboratory.
Cobas 8000® System (Roche) was utilized for fasting blood sugar, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides levels.
An immunoassay method utilized for follicular stimulating hormone (FSH), leutinizing hormone (LH), estradiol and testosterone levels using the Architect 12000SR® equipment (Abbott). Serial verification methods namely precision, accuracy, linearity and method comparison studies was performed to validate the results, with intra-assay CVs 2.3-4.1%, 2.2-2.6%; 4.4-10%, and 2.9-5.0%, respectively;
and inter-assay CVs 5.3-6.6% and 4.9-6.3%, 8.8-12.4%, and 9.1-10.9%, respectively.
Histology
Microscopic examination was performed using a standard histology protocol. The tissue samples were fixed in 10% buffered formalin before they were cut into thin sections. The sections were then paraffin-embedded following graded ethanol dehydration and paraffin infiltration. Sections 3 to 10 microns in thickness were cut from paraffin block using microtome. The sections were stained with hematoxylin and eosin (H&E) before mounted on a glass slide and covered with a thin cover glass to seal the preparation. The sections were examined using a light microscope (Carl Zeiss).
Quantitative real-time polymerase chain reaction (qPCR)
RNA extraction from endometrial tissue was performed using the QIAshredder kit (Qiagen, Valencia, CA) and further purified using the QIAamp® Mini-kit (Qiagen, Valencia, CA), after the samples were measured to ensure similar volume. The RNA concentration and quality was checked using Nanodrop®.. Reverse transcription were performed using the Superscript® III First-Strand Synthesis System (Invitrogen TM ). A total RNA of 60ng was prepared for the reaction. 0.19ng/mL, 0.38ng/mL, 0.75ng/mL, 1.5ng/mL, 3ng/mL, 6ng/mL and 12ng/mL) were analysed in duplicate. The intra-assay CV for IGF1, IGFBP1 and PTEN were 3.0-4.0%, 7.5-8.5% and 2.5-3.6%
respectively; inter-assay CV 8.3-8.8%, 9.5-21% and 4.6-9.7% respectively.
The samples were left at room temperature ( The microplate reader was run and conducted measurement at 450nm after ensuring no bubble in the well and any fingerprint or liquid at the bottom of plate been cleared. The optical density value was plotted against the standard protein concentration to create a standard curve. The protein quantification in the groups was determined. The data was analysed using Prism GraphPad 6.
Sample size and Statistics
The sample size was calculated to detect a 40% difference in IGF1 gene expression in women with PCOS compared with controls and women with PCOS compared with endometrial cancer. Thirty four women were required in each arm for a study with a power of 80% at a 5% significance level. A difference of 40% was chosen based on a study (Gloria et al, 2003) in which IGF1 gene levels in women with endometrial cancer were compared were compared with controls. Sixty seven percent of the endometrial cancer samples expressed IGF1 gene compared with 27% in the control group (a 40% difference). A 5% significance level was chosen to allow for 2 comparisons; PCOS versus controls and PCOS versus endometrial cancer. depended on the number of independent variables, and a One-Way-ANOVA test was used for comparing differences in more than 2 groups with an independent T-test used for comparing mean differences between two groups. A Spearman correlation coefficient test was used to check for association between variables, in non-parametric variables. A p-value of less than 0.05 was considered statistically significant. Age and BMI-adjusted analysis was performed due to the significant difference mean in the groups.
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Results
Participants' characteristic data
A summary of the participants' characteristic data is presented in Among 34 participants with EC, four of them were premenopausal, 13 were perimenopausal and 17
were postmenopausal. Grade 2 endometroid adenocarcinoma was more prevalence (44.1%), followed by grade 3 (29.4%) and grade 1 (26.5%) in the EC group. In controls group, 20 were premenopausal and 14 were postmenopausal, and all were confirmed to have benign diseases.
Gene expression in PCOS, endometrial cancer and control
IGF1 expression was significantly increased in both PCOS (p<0.001) and EC (p=0.0006) compared to controls. However there was no significant difference between PCOS and EC (p=0.220). IGFBP1 expression was also significantly increased in PCOS (p<0.001) and EC (p=0.001) compared to controls. However there was no difference between PCOS and EC (p=0.462). PTEN expression was significantly increased in both PCOS (p=0.007) and EC (p<0.001) compared to controls. But, again the PTEN expression was not statistically significant difference among PCOS and EC (p=0.607) 
Correlation between gene expression and BMI
Spearman correlation test was used to determine the correlation of gene expression to BMI. IGF1 expression was not significantly correlated with BMI in PCOS (r=0.083, 95% CI=-0.419 to 0.272, 
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Correlation between gene expression and waist-hip-ratio (WHR)
As WHR was normally distributed but the gene expression was a continuous not normally distributed ELISA specific protein validation in serum Figure 1 illustrates the concentration of IGF1 protein in the serum of PCOS and EC compared to control. IGF1 level was significantly higher in PCOS compared to control (p=0.023). A similar trend M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT 11
was observed in EC compared to control (p<0.001). In addition, serum IGF1 levels was significantly higher in EC compared with PCOS women EC (p=0.005). Figure 3 illustrates the concentration of PTEN protein in the serum of PCOS and EC compared to control. PTEN levels were significantly higher in PCOS compared to control (p=0.025). A similar trend was observed in EC compared to controls (p=0.042). However, there was no significantly difference in serum PTEN levels between PCOS and EC (p=0.753).
Discussion
As far as we know from our literature search, this is the first study that has investigated the expression of genes involved in the insulin signaling pathway in the human PCOS endometrium compared to expression in endometrial biopsies from women with endometrial cancer (EC). The genes investigated, included IGF1, IGFBP1 and PTEN. All three genes were significantly expressed in both PCOS and EC endometrium compared to endometrial biopsies from control women without PCOS and without EC. Furthermore, there was no significant difference in the expression of IGF1, IGFBP1 and PTEN genes in women with PCOS compared with EC (P>0.05). These findings were reflected in the serum protein levels. The changes in gene expression were independent of body mass index, waist hip ratio or systemic measurements of insulin resistance using the homeostatic model assessment (HOMA-IR). The changes were also independent of systemic estradiol and androgen levels as estradiol levels were lowest in women with EC compared to the levels in PCOS and control women and androgen levels similar in EC and controls despite the up-regulation of the 
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In addition, our findings were inconsistent with previous studies that investigated a link between obesity and IGF expression, obesity and serum IGFBP protein, and obesity to serum IGF1 protein level (Kelly et al, 2011) . We found in our study that IGF1 up-regulation was independent of BMI.
IGFBP1 and IGF1 genes were similarly up-regulated and that up-regulation of PTEN gene was present in EC. A population study in a tertiary centre for example, found that the mean weight of PCOS women was 37.3 +/-9.9 kg/m 2 (obese) (Yildiz et al, 2008) , and out of 3,947 EC patients in a retrospective cohort study, 62% were obese and morbidly obese (Mahdi et al, 2014) . Hence it has been suggested that obesity might link PCOS with EC. The results from our study which found that the up-regulation of IGF1, IGFBP1 and PTEN genes in PCOS women were independent of obesity (as PCOS women had a similar mean BMI to controls), however suggests that the women with PCOS might be at higher risk of EC independent of BMI.
Although increased IGF1 protein levels in circulation are associated with lower levels of IGFBP this was not reflected at the molecular level in our study as both genes were up-regulated in PCOS and EC endometrium. However, it is plausible that both genes may independently modulate EC risk in PCOS at the cellular level. It has been for example been suggested that IGFBP1 could increase the concentration of ligands in the tumour microenvironment which then modulates the Wnt signaling pathways (Declercq et al, 2008) . The Wnt pathway is involved in embryonic development, including cell division and migration and it has a strong association with cancer development. In breast cancer, increased expression of beta-catenin (an indicator for Wnt activation) correlated with poor prognosis.
(Vadnais et al, 2014).
PTEN is tumor suppressor gene. Mutation or loss of function of this gene is associated with higher risks of cancer and poorer prognosis (Fernández et al, 2014) . However in our study, the expression of PTEN was up-regulated in both PCOS and EC. Seemingly, with this finding, the potential risk of EC is supposed to be reduced in PCOS. In EC women, hypothetically the prognosis of EC would also be expected to be improved with up-regulation of PTEN as found in our study. However, it also plausible that PTEN up-regulation as found in both women with PCOS and EC in our study may be linked with increased cancer risk. A recent study investigated the functional level of PTEN in astrocyte growth and found that a 'gain of function mutation' could reverse the tumour suppressor role of PTEN (Fernández et al, 2014) . It was suggested that this gain of function mutation contributes to atypical cell growth in part through up-regulation of the mitogenic IGF-1/PI3K/Akt, (Fernández et al, 2014) .
However, it is inconclusive whether the 'gain of function mutation' theory could fit with our findings where IGF1 and PTEN genes, were similarly increased in expression in PCOS and EC. This 'gain of function mutation', converting PTEN into a tumour promoter involving the IGF1 pathway is relative a novel hypothesis that requires further assessment especially in the context of EC and PCOS.
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